Innovus Pharma (INNV) Commences Vesele Combo Safety, Efficacy Program
- S&P 500 closes higher to secure strongest Q1 since 2019
- UBS sees 5 warnings signals on semiconductor chip stocks
- US consumer sentiment tops estimates in March to hit nearly 3-yr high, UMich says
- Reddit (RDDT) stock continues to slide as short-sellers eye stock
- Estée Lauder (EL) climbs as BofA upgrades to Buy on profit recovery expectations
- AMC Entertainment (AMC) enters into an equity distribution agreement
- Kerrisdale Capital is short Microstrategy (MSTR), long bitcoin
- Discover Financial Services (DFS) Announces CEO Resignation
- Intuitive Machines (LUNR) Files for $300M Share Offering, 160M Share Offering by Selling Stockholders
- AMC Entertainment (AMC) Enters $250M ATM Agreement
Innovus Pharma Initiates Pre-Clinical and Clinical Program Evaluating the Safety and Efficacy of Vesele® with Sildenafil (Viagra®)
October 5, 2016 6:00 AM EDTStudies Aimed at Quantifying Nitric Oxide Production and Erectile Dysfunction International Score (IIEF)
SAN DIEGO--(BUSINESS WIRE)-- Innovus Pharmaceuticals, Inc. ("Innovus Pharma") (OTCQB Venture Market: INNV), an emerging commercial stage pharmaceutical company delivering over-the-counter medicines and consumer care products for mens and women's health and respiratory diseases, announced today the initiation of a pre-clinical and... More